Patents Assigned to Amunix Pharmaceuticals, Inc.
  • Patent number: 12215156
    Abstract: Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: February 4, 2025
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Eric Johansen, Angela Henkensiefken, Darragh Maccann, James McClory, Philipp Kuhn, Andre Frenzel, Bryan Irving, Mika Derynck
  • Patent number: 12071456
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 27, 2024
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Patent number: 12060424
    Abstract: The present invention relates to activatable recombinant polypeptide compositions comprising a cleavage release segment. In some instances, the activatable recombinant polypeptide compositions include an XTEN linked to binding moieties by cleavable release segments that, when cleaved, the binding moieties are capable of binding together effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable activatable recombinant compositions.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 13, 2024
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Fan Yang, Volker Schellenberger, Vladimir Podust, Bee-Cheng Sim, Desiree Thayer, John Beaber
  • Patent number: 11981744
    Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: May 14, 2024
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Volker Schellenberger, Fan Yang, Desiree Thayer, Bee-Cheng Sim, Chia-Wei Wang
  • Patent number: 11713358
    Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: August 1, 2023
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Volker Schellenberger, Fan Yang, Desiree Thayer, Bee-Cheng Sim, Chia-Wei Wang
  • Patent number: 10961287
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 30, 2021
    Assignee: Amunix Pharmaceuticals, Inc
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Patent number: 10953073
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 23, 2021
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • Patent number: 10870874
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 22, 2020
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. C. Stemmer, Nathan C. Geething